About the Company
The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector COVID-19 vaccine developed by the United States-based pharmaceutical company ImmunityBio.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on ImmunityBio, Inc.
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
We recently published 12 Best Healthcare Stocks to Buy Under $30. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best ...
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published 10 Stocks With Whopping 11-97% Upside. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing ...
ImmunityBio Wins U.K. Approval
Culver City-based ImmunityBio Inc. has started to take its Anktiva immunotherapy drug global. Last month, the United Kingdom ...
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment
Immunitybio Inc (($IBRX)) announced an update on their ongoing clinical study. ImmunityBio Inc. is conducting a study titled ‘Single Arm Study to ...
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
Contacts Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 858-746-9289 Hemanth.Ramaprakash@ImmunityBio.com Media Sarah Singleton ImmunityBio +1 415-290-8045 Sarah.Singleton@ImmunityBio.com ...
What's Going On With ImmunityBio Stock? - Benzinga
ImmunityBio shares are moving on heavy trading volume Friday. According to data from Benzinga Pro, more than 26.6 million shares have been traded in the session, compared to the stock’s 100-day ...
ImmunityBio Reports Third-Quarter 2024 Financial Results
ImmunityBio, Inc. today announced its financial results for the third-quarter ended September 30, 2024. ImmunityBio has secured coverage for over 200 million medical lives through medical ...
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body’s natural defenses.
ImmunityBio, Inc. Announces Execution of $80 Million ... - Morningstar
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations.
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an ...
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
ImmunityBio, Inc., a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public ...
Similar Companies
Loading the latest forecasts...